| Literature DB >> 16425126 |
Marie-Laure Chaix1, Didier Koumavi Ekouevi, Francois Rouet, Besigin Tonwe-Gold, Ida Viho, Laurence Bequet, Gilles Peytavin, Hassane Toure, Herve Menan, Valeriane Leroy, Francois Dabis, Christine Rouzioux.
Abstract
The frequency of resistance mutations was estimated in the cohort of Agence Nationale de Recherches sur le SIDA Ditrame Plus, a study that evaluated the combination of short-course zidovudine (ZDV) plus lamivudine (3TC) and single-dose nevirapine (SD-NVP) followed by 3 days of postpartum ZDV plus 3TC for the prevention of mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1). The frequency with which resistance mutations were detected in mothers at week 4 postpartum was 1.14% (95% confidence interval [CI], 0.03%-6.17%) for NVP and 8.33% (95% CI, 3.66%-15.76%) for 3TC. In multivariate analysis, 3TC resistance was associated with a longer duration of ZDV plus 3TC prepartum prophylaxis (P=.009). This regimen, which is feasible in resource-limited settings, prevents most peripartum HIV-1 transmission and minimizes the development of NVP resistance.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16425126 DOI： 10.1086/499966
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226